eBook | Facing Up to the Biosimilar Challenge: Preclinical and Beyond

Faced with the double whammy of a continuing economic crisis and an aging and increasingly obese population, healthcare providers are seeing where they can cut costs. One of the key targets for cutting is the drugs bill, especially as the burden on the healthcare system is increasing at the same time as drug costs are climbing.

Biologics can be safer and better targeted than small-molecule drugs and have potential to reduce the progress of diseases, improving quality of life and allowing people to continue working and maintaining independence for longer. But this comes with a high price tag, with the increased development and manufacturing costs.

To read more on the biosimilar challenge, complete the form to the right to download your copy of this eBook today!

Sponsored By: